基于网络药理学的复方血栓通治疗糖尿病视网膜病的药理机制研究

Pharmacological mechanism of Compound Xueshuantong in treatment of diabetic retinopathy based on network pharmacology

利用网络药理学发现复方血栓通治疗糖尿病视网膜病的药理机制。采用TCMSP软件检索复方血栓通的活性成分,并且得到其活性成分对应的靶点;然后通过OMIM、TTD、pharm Gkb、Di GSe E和GAD5个数据库检索糖尿病视网膜病相关靶点;两者取交集得到37个相同的靶点。用Systems Dock在线分子对接工具验证结果。使用DAVID软件对37个靶点进行GO注释分析和KEGG通路分析。采用Cytoscape 3.6.1软件建立活性成分-靶点-通路网络模型。网络药理学研究提示,复方血栓通可能通过血管内皮生长因子信号通路、丝裂原活化蛋白激酶信号通路和Toll样受体信号通路等多个通路治疗糖尿病视网膜病,体现了中药复方多成分、多靶点、多通路的特点。此研究为进一步阐释复方血栓通治疗糖尿病视网膜病的药理机制提供了理论依据。

The aim of this study was to discover the pharmacological mechanism of Compound Xueshuantong in the treatment of diabetic retinopathy using network pharmacology. TCMSP software was used to search the active ingredients of Compound Xueshuantong, and the targets of its active ingredients were obtained. The targets of diabetic retinopathy were searched by OMIM, TTD, pharm Gkb, Di GSe E and GAD database. The same 37 targets were analyzed by GO and KEGG using DAVID software. The results were verified using the Systems Dock. Cytoscape 3.6.1 software was used to establish an ingredient-target-pathway network model. Network pharmacological studies suggest that Compound Xueshuantong treated diabetic retinopathy through the vascular endothelial growth factor signaling pathways, mitogen-activated protein kinase signaling pathways and Toll-like receptor signaling pathways. Compound Xueshuantong alleviated diabetic retinopathy through multi-component, multi-target, and multi-pathway. This study provides a theoretical basis for further elucidation of the pharmacological mechanism of Compound Xueshuantong in the treatment of diabetic retinopathy.